Suchergebnisse - "Vignetti, M"

PubPharm (101)

1

Covid-19 in Philadelphia-negative myeloproliferative neoplasms : a GIMEMA survey on incidence, clinical management and vaccine

enthalten in: Leukemia | 2022

von Breccia, M. | Piciocchi, A. | Messina, M. | +12

2

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

enthalten in: The pharmacogenomics journal | 2018

von Visani, G. | Loscocco, F. | Ruzzo, A. | +19

3

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2016

von Platzbecker, U. | Avvisati, G. | Cicconi, L. | +42

4

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT

enthalten in: Bone marrow transplantation | 2015

von Hengeveld, M. | Suciu, S. | Chelgoum, Y. | +17

5

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT

enthalten in: Bone marrow transplantation | 2015

von Hengeveld, M. | Suciu, S. | Chelgoum, Y. | +17

6

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) : phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

enthalten in: Annals of hematology | 2014

von Willemze, R. | Suciu, S. | Muus, P. | +9

7

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

enthalten in: Annals of hematology | 2014

von Willemze, R. | Suciu, S. | Muus, P. | +9

8

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

enthalten in: Annals of hematology | 2014

von Willemze, R. | Suciu, S. | Muus, P. | +9

9

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

enthalten in: Annals of hematology | 2014

von Willemze, R. | Suciu, S. | Muus, P. | +9

10

Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial

enthalten in: Leukemia | 2014

von Cortelezzi, A. | Sciumè, M. | Liberati, A. | +23

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]